Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
Rapport Therapeutics (NASDAQ: RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in two major healthcare investor conferences in June 2025.
The company will participate in fireside chats at the Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 10:30 a.m. ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9, 2025, at 10:00 a.m. ET. Both presentations will be accessible via webcast on the company's investor relations website.
Rapport Therapeutics (NASDAQ: RAPP), una società biotech in fase clinica specializzata nello sviluppo di farmaci di precisione a piccola molecola per disturbi neurologici e psichiatrici, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a giugno 2025.
La società parteciperà a discussioni informali al Jefferies Global Healthcare Conference a New York il 4 giugno 2025 alle 10:30 ET, e al Goldman Sachs 46th Annual Global Healthcare Conference a Miami il 9 giugno 2025 alle 10:00 ET. Entrambe le presentazioni saranno disponibili in webcast sul sito web delle relazioni con gli investitori della società.
Rapport Therapeutics (NASDAQ: RAPP), una empresa biotecnológica en etapa clínica enfocada en desarrollar medicamentos de precisión de pequeñas moléculas para trastornos neurológicos y psiquiátricos, ha anunciado su participación en dos importantes conferencias para inversores del sector salud en junio de 2025.
La compañía participará en charlas informales en la Jefferies Global Healthcare Conference en la ciudad de Nueva York el 4 de junio de 2025 a las 10:30 a.m. ET, y en la Goldman Sachs 46th Annual Global Healthcare Conference en Miami el 9 de junio de 2025 a las 10:00 a.m. ET. Ambas presentaciones estarán disponibles vía webcast en el sitio web de relaciones con inversores de la empresa.
Rapport Therapeutics (NASDAQ: RAPP)는 신경 및 정신 질환을 위한 소분자 정밀 의약품 개발에 중점을 둔 임상 단계 생명공학 회사로, 2025년 6월 두 개의 주요 헬스케어 투자자 컨퍼런스에 참여할 것이라고 발표했습니다.
회사는 2025년 6월 4일 오전 10시 30분(동부시간)에 뉴욕에서 열리는 Jefferies Global Healthcare Conference와 2025년 6월 9일 오전 10시(동부시간)에 마이애미에서 열리는 Goldman Sachs 제46회 연례 글로벌 헬스케어 컨퍼런스에서 파이어사이드 채팅에 참여할 예정입니다. 두 발표 모두 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
Rapport Therapeutics (NASDAQ : RAPP), une entreprise biotechnologique en phase clinique spécialisée dans le développement de médicaments de précision à petites molécules pour les troubles neurologiques et psychiatriques, a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé en juin 2025.
L'entreprise participera à des discussions informelles lors de la Jefferies Global Healthcare Conference à New York le 4 juin 2025 à 10h30 (heure de l'Est), ainsi qu'à la Goldman Sachs 46th Annual Global Healthcare Conference à Miami le 9 juin 2025 à 10h00 (heure de l'Est). Les deux présentations seront accessibles en webcast sur le site des relations investisseurs de la société.
Rapport Therapeutics (NASDAQ: RAPP), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von präzisionsmedizinischen Kleinmolekülen für neurologische und psychiatrische Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei bedeutenden Gesundheitsinvestorenkonferenzen im Juni 2025 angekündigt.
Das Unternehmen wird am 4. Juni 2025 um 10:30 Uhr ET an Fireside-Chats auf der Jefferies Global Healthcare Conference in New York City und am 9. Juni 2025 um 10:00 Uhr ET auf der Goldman Sachs 46th Annual Global Healthcare Conference in Miami teilnehmen. Beide Präsentationen werden über einen Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein.
- None.
- None.
BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences.
Jefferies Global Healthcare Conference (New York City) - fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time.
Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL) - fireside chat on Monday, June 9, 2025, at 10:00 a.m. Eastern Time.
Interested parties may access the live and archived webcasts of these fireside chats under the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR, Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
What upcoming investor conferences will Rapport Therapeutics (RAPP) attend in June 2025?
When is Rapport Therapeutics' (RAPP) presentation at the Jefferies Global Healthcare Conference?
How can investors access Rapport Therapeutics' (RAPP) conference presentations?
What type of medicines does Rapport Therapeutics (RAPP) develop?
